Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

GeoVax Labs, Inc. GOVX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
48/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$4.00
+198.5%

GeoVax Labs, Inc. (GOVX) is a Biotechnology company in the Healthcare sector, currently trading at $1.34. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is GOVX = $4 (+198.5% upside).

Valuation: GOVX trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).

Financials: revenue is $4M, -89.5%/yr average growth. Net income is $25M (loss), growing at -19.1%/yr. Net profit margin is -632% (negative). Gross margin is 97.6% (+4037.6 pp trend).

Balance sheet: total debt is $0 against $5.0T equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.55 (strong liquidity). Debt-to-assets is 0%. Total assets: $8M.

Analyst outlook: 6 / 7 analysts rate GOVX as buy (86%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$4.00
▲ 198.51% Upside
Average Price Target
The 12-month price target for GeoVax Labs, Inc. is $4.00.

GOVX SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GOVX

✓
VALUE Pass
100/100
GOVX trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25). Forward PEG -0.01 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $4, implying +198.5% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GOVX: -89.5%/yr revenue is, -19.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet GOVX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.55 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
GOVX: Gross margin is 97.6% (+4037.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 6 / 7 analysts rate GOVX as buy (86%). Analyst consensus target is $4 (+198.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
GOVX: Net profit margin is -632%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.26-34.75
Volume63.82K
Avg Volume (30D)121.52K
Market Cap$1.36M
Beta (1Y)3.81
Share Statistics
EPS (TTM)-4.82
Shares Outstanding$5.19M
IPO Date2020-09-25
Employees17
CEODavid Alan Dodd
Financial Highlights & Ratios
Revenue (TTM)$3.95M
Gross Profit$3.86M
EBITDA$-24.88M
Net Income$-24.99M
Operating Income$-25.14M
Total Cash$5.51M
Net Debt$-5.51M
Total Assets$8.16M
Price / Earnings (P/E)-0.3
Price / Sales (P/S)0.34
Analyst Forecast
1Y Price Target$4.00
Target High$4.00
Target Low$4.00
Upside+198.5%
Rating ConsensusBuy
Analysts Covering7
Buy 86% Hold 14% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS3736787058

Price Chart

Track all markets on TradingView
GOVX
GeoVax Labs, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.26 52WK RANGE 34.75

People Also View

ATNF
ATNF
180 Life Sciences Corp.
$7.04
-7.49%
 OCGN
OCGN
Ocugen, Inc.
$1.80
+0.56%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 IBIO
IBIO
iBio, Inc.
$2.19
-0.45%
 ONTX
ONTX
Onconova Therapeutics, Inc.
$1.00
-0.47%
 PHIO
PHIO
Phio Pharmaceuticals Corp.
$1.29
+4.03%
 APGN
APGN
Apexigen, Inc.
$0.39
+8.48%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message